Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Japanese shares rise amid stock rotation ahead of financial year-end

03/08/2021 | 09:41pm EDT

TOKYO, March 9 (Reuters) - Japanese shares rose on Tuesday as investors sold technology stocks and shifted some of those funds to consumer goods companies expected to benefit from an economic recovery from the pandemic.

The Nikkei 225 Index climbed 0.20% to 28,805.46 by 0206 GMT. The broader Topix rose 0.66% to 1,906.20.

Technology and energy stocks fell as some investors booked profits before the fiscal year ends on March 31.

On the positive side, consumer cyclicals and real estate shares rose because they are closely tied to the domestic economy, which is expected to pick up as the year progresses.

However, the broader market may lack direction in the coming weeks after rallying to a more than 30-year high last month, which some investors said was a sign of excessive froth.

"There is some selling in the IT sector, but at the same time investors are willing to buy the dip for value shares that are linked to the domestic economy," said Ayako Sera, a market strategist at Sumitomo Mitsui Trust Bank.

"You can tell that investors are planning for life after the coronavirus pandemic, but the market is likely to consolidate around current levels."

The stocks that gained the most among the top 30 core Topix names were Astellas Pharma Inc, up 3.36%, followed by Honda Motor Co Ltd, gaining 3.46%.

Many exporters got a boost after the yen fell to a nine-month low against the dollar. A weaker yen inflates exporters' earnings when repatriated from overseas.

The underperformers among the Topix 30 were Nidec Corp , down 4.59%, followed by Nintendo Co Ltd, losing 2.91%.

There were 156 advancers on the Nikkei index against 69 decliners.

The volume of shares traded on the Tokyo Stock Exchange's main board was 0.74 billion, compared to the average of 1.38 billion in the past 30 days. (Reporting by Stanley White; Editing by Subhranshu Sahu)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 0.37% 1912 End-of-day quote.19.95%
HONDA MOTOR CO., LTD. 1.09% 3418 End-of-day quote.18.78%
NIDEC CORPORATION 2.44% 13000 End-of-day quote.0.15%
NIKKEI 225 0.58% 27548 Real-time Quote.-0.20%
NINTENDO CO., LTD. -0.25% 59820 End-of-day quote.-9.13%
All news about ASTELLAS PHARMA INC.
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplem..
CI
07/15Piers Morgan Joins Pharnext's Board of Directors
DJ
07/15Piers Morgan rejoint le Conseil d'Administration de Pharnext
DJ
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 ..
CI
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 S..
CI
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
AQ
07/11ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
PU
07/09ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
BU
06/29ASTELLAS PHARMA : Corporate Governance Report
PU
06/28ASTELLAS PHARMA : Receives Positive CHMP Opinion for EVRENZO (roxadustat) for Ad..
PU
More news
Financials
Sales 2022 1 320 B 11 935 M 11 935 M
Net income 2022 204 B 1 845 M 1 845 M
Net cash 2022 425 B 3 840 M 3 840 M
P/E ratio 2022 17,3x
Yield 2022 2,55%
Capitalization 3 543 B 32 055 M 32 043 M
EV / Sales 2022 2,36x
EV / Sales 2023 2,07x
Nbr of Employees 15 455
Free-Float 99,0%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 1 912,00 JPY
Average target price 2 470,77 JPY
Spread / Average Target 29,2%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.19.95%33 619
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246